Unapproved Drugs Initiative is a program by the U.S Food and Drug Administration announced in June 2006 to remove unapproved drugs from the market.[1]
As of October 2011[update] some 14 categories of drugs have been affected.[2]
It has been controversial due to the resulting increase in some drug prices.
In April 2010, in an editorial in the New England Journal of Medicine (NEJM), A.S. Kesselheim and D.H. Solomon said that the rewards of this legislation are not calibrated to the quality or value of the information produced, that there is no evidence of meaningful improvement to public health, that it would be much less expensive for the FDA or National Institutes of Health to pay for trials themselves on widely available drugs such as colchicine, and that the cost burden falls primarily on patients or their insurers.[3] URL Pharma posted a detailed rebuttal of the NEJM editorial.[4]
Drugs affected
edit- Colchicine, (pill price rose from $0.09 to $4.85)
- Ergotamine
- Albuterol
- many others[2]
References
edit- ^ "Unapproved Drugs Initiative (fda.gov)". Food and Drug Administration.
- ^ a b "Enforcement Actions by Drug Class". Food and Drug Administration.
- ^ Kesselheim AS, Solomon DH (June 2010). "Incentives for drug development--the curious case of colchicine". N. Engl. J. Med. 362 (22): 2045–7. doi:10.1056/NEJMp1003126. PMID 20393164.
- ^ Response from URL Pharma
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |